Kamada News and Activities

Kamada is a company listed under the stock ticker KMDA (IL).

View the org chart displaying its 22 main executives

Most searched biographies at Kamada

• Amir London, Chief Executive Officer
• David Tsur, Vice Chairman of the Board
• Leon Recanati, Director

Create your alert
to follow the executive moves at Kamada.

Kamada has 1,914 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Zymeworks has announced the acquisition of Theravance Biopharma  (posted on June 29 2026).
• Aurobindo has announced the acquisition of Lannett  (posted on June 26 2026).
• Merck has announced the acquisition of Bio-Techne  (posted on June 25 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Kamada

• Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory - Kamada Pharmaceuticals
• Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year - Kamada Pharmaceuticals
• News - Kamada Pharmaceuticals
• Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026 - Kamada Pharmaceuticals
• Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders - Kamada Pharmaceuticals
• Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas - Kamada Pharmaceuticals
• Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth - Kamada Pharmaceuticals
• Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy - Kamada Pharmaceuticals
• Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 - Kamada Pharmaceuticals
• Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance - Kamada Pharmaceuticals
• View more press releases Close

Social media about Kamada

• Kamada on Wikipedia, Google News & Yahoo Finance
• Kamada on LinkedIn, X (Twitter) & YouTube